The pharmacodynamic effects of rocuronium in morbidly obese patients [Morbid Obez Hastalarda Rokuronyumun Farmakodinamik Etkileri]

Basit Öğe Kaydı
dc.contributor.authorAnkan N.
dc.contributor.authorAlper I.
dc.contributor.authorUlukaya S.
dc.contributor.authorBalcioglu S.T.
dc.contributor.authorYegül I.
dc.date.accessioned2019-10-26T22:58:23Z
dc.date.available2019-10-26T22:58:23Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractAim: In this study, we aimed to investigate the pharmacodynamic effects of rocuronium when dosed according to real or ideal body weights of morbidly obese patients and compare the results with normal body weight patients. Material and Methods: Sixteen morbidly obese patients (body mass index [BMI] >40 kg/m- 2) and 8 patients with normal body weights (BMI <30 kg/m- 2, control group) were given rocuronium (0.6 mg/kg iv) during application of anaesthesia The dose of rocuronium was based on the real (RBW, n=8) or ideal body weights (IBW, n=8) in morbidly obese patients. The neuromuscular blockade properties of three groups were compared. Results: The median onset time of rocuronium in the IBW group was significantly longer than that in the RBW and control group (210 versus 80 and 105 sec, respectively; p<0.05), while the duration of action was significantly shorter (28 versus 66 and 42 min, p<0.05). Any statistically significant difference in the recovery index were found between the groups (3.5 vs 4.5 and 2.5 min, p>0.05). Conclusion: Dosing rocuronium according to the ideal body weights in morbidly obese patients resulted in delayed onset time and shorter clinical duration when compared to the patients with normal body weights or morbidly obese patients who received rocuronium based on their real body weights. In addition to the type and duration of the operation, individually adjusted dosing may be required in morbidly obese patients when more rapid induction is necessary.en_US
dc.identifier.endpage239en_US
dc.identifier.issn1304-0871
dc.identifier.issn1304-0871en_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage234en_US
dc.identifier.urihttps://hdl.handle.net/11454/20501
dc.identifier.volume37en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofTurk Anesteziyoloji ve Reanimasyon Dernegi Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMorbid obesityen_US
dc.subjectNeuromuscular monitoringen_US
dc.subjectRocuroniumen_US
dc.titleThe pharmacodynamic effects of rocuronium in morbidly obese patients [Morbid Obez Hastalarda Rokuronyumun Farmakodinamik Etkileri]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu